Tuesday, February 3, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Newell Brands Shares Plummet Following Disappointing Earnings Report

Robert Sasse by Robert Sasse
November 3, 2025
in Analysis, Consumer & Luxury, Earnings
0
Newell Brands Stock
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter

The consumer goods sector is undergoing a significant transformation, and Newell Brands finds itself at the center of this challenging period. The company’s stock reached unprecedented lows after the release of disappointing quarterly results that fell far below market expectations.

Third Quarter Performance Reveals Substantial Challenges

For the third quarter of 2025, reported on October 31, Newell Brands disclosed a 7.2% decline in net sales, which fell to $1.806 billion. The company’s core sales experienced an even steeper contraction, dropping by 7.4%. This performance was primarily driven by three key factors: reduced retail inventory levels, international market difficulties—with particular weakness in Brazil—and diminished consumer response to tariff-related price increases.

Despite these revenue challenges, the company managed to post a profit of $21 million, marking an improvement from the loss recorded during the same period in the previous year. However, this positive development was tempered by a contraction in gross margin, which settled at 34.1%. This margin pressure stemmed from tariff expenses, volume reductions, and inflationary pressures. Notably, excluding one-time China tariffs totaling $24 million, the company’s margin would have shown modest expansion.

Revised Outlook Intensifies Investor Concerns

Market sentiment deteriorated further when management substantially lowered its full-year guidance. The company now anticipates earnings per share in the range of $0.56 to $0.60, signaling that current headwinds are expected to persist throughout the coming months. A significant factor impacting this outlook is the projected tariff costs of approximately $180 million for the full year, which will continue to exert pressure on profitability.

Should investors sell immediately? Or is it worth buying Newell Brands?

The market response to these developments was immediate and severe. Newell Brands’ equity value declined by approximately 28% following the announcement, establishing new record lows. Since the beginning of the year, the stock has surrendered more than two-thirds of its value, creating substantial losses for shareholders.

Navigating Multiple Operational Challenges

Newell Brands currently confronts several simultaneous operational hurdles. Management cited “significant trade disruptions” resulting from tariffs, a challenging consumer spending environment, and persistent international weaknesses as creating substantial pressure on business operations. While the quarterly profit provided some relief to the company’s balance sheet, underlying structural issues remain unaddressed.

The critical question facing investors is whether this consumer goods conglomerate can reverse its downward trajectory. Current financial results and the reduced guidance offer limited optimism for a near-term recovery. As the entire industry undergoes transformation, Newell Brands faces one of the most significant tests in its recent corporate history.

Ad

Newell Brands Stock: Buy or Sell?! New Newell Brands Analysis from February 3 delivers the answer:

The latest Newell Brands figures speak for themselves: Urgent action needed for Newell Brands investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 3.

Newell Brands: Buy or sell? Read more here...

Tags: Newell Brands
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Acadia Stock
Analysis

Setback in Europe Clouds Growth Outlook for Acadia

February 3, 2026
QuantumScape Stock
Analysis

QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation

February 3, 2026
CNO Stock
Analysis

CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

February 3, 2026
Next Post
Kura Oncology Stock

Pivotal Week Ahead for Kura Oncology Investors

Wabtec Stock

Wabtec Shares Poised for Growth on Strong Quarterly Performance

Natera Stock

Natera Shares Approach Critical Earnings Test

Recommended

Biotechnology Trading online

Decline in Short Interest for Adobe NYSE ADBE Signals Bullish Sentiment

2 years ago
Cisco Stock

Cisco Stock Surges as Artificial Intelligence Drives Infrastructure Demand

3 months ago
Adaptive Biotechnologies Stock

Strategic Shift: Adaptive Biotechnologies Severs Major Pharma Alliance

6 months ago
Puma Stock

Puma Shares Face Critical Test Amid Mounting Challenges

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Q2 Holdings to Report Full-Year 2025 Financial Results

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

Commerce Bancshares Surpasses Market Forecasts in Year-End Report

Strategic Moves at Genworth Financial Ahead of Earnings

BancFirst Strengthens Regional Footprint with Acquisition Finalization

iShares MAFE ETF Reaches Fresh 52-Week Peak

Trending

Acadia Stock
Analysis

Setback in Europe Clouds Growth Outlook for Acadia

by Robert Sasse
February 3, 2026
0

Acadia Pharmaceuticals has encountered a significant obstacle for its European expansion strategy. Market uncertainty followed the announcement...

QuantumScape Stock

QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation

February 3, 2026
CNO Stock

CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

February 3, 2026
Q2 Holdings Stock

Q2 Holdings to Report Full-Year 2025 Financial Results

February 3, 2026
SpringWorks Therapeutics Stock

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

February 3, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Setback in Europe Clouds Growth Outlook for Acadia
  • QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation
  • CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com